164 related articles for article (PubMed ID: 38588887)
21. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients.
Abu Al Karsaneh O; Al Anber A; ALQudah M; Al-Mustafa S; AlMa'aitah H; Sughayer M
Diagn Pathol; 2023 Jun; 18(1):75. PubMed ID: 37340403
[TBL] [Abstract][Full Text] [Related]
22. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
23. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
26. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
Ichikawa H; Usui K; Aizawa M; Shimada Y; Muneoka Y; Kano Y; Sugai M; Moro K; Hirose Y; Miura K; Sakata J; Yabusaki H; Nakagawa S; Kawasaki T; Umezu H; Okuda S; Wakai T
BMC Cancer; 2024 Jun; 24(1):719. PubMed ID: 38862927
[TBL] [Abstract][Full Text] [Related]
27. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
[TBL] [Abstract][Full Text] [Related]
28. NSCLC and HER2: between lights and shadows.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
[TBL] [Abstract][Full Text] [Related]
29. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
30. Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.
Stein MK; Morris L; Sullivan JL; Fenton M; VanderWalde A; Schwartzberg LS; Martin MG
Med Oncol; 2017 Jul; 34(7):126. PubMed ID: 28573640
[TBL] [Abstract][Full Text] [Related]
31. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
Yokoyama T; Kondo M; Goto Y; Fukui T; Yoshioka H; Yokoi K; Osada H; Imaizumi K; Hasegawa Y; Shimokata K; Sekido Y
Cancer Sci; 2006 Aug; 97(8):753-9. PubMed ID: 16863509
[TBL] [Abstract][Full Text] [Related]
32. Non-amplification genetic alterations of
Mehta A; Nathany S; Tripathi R; Sharma SK; Saifi M; Batra U
J Clin Pathol; 2021 Feb; 74(2):106-110. PubMed ID: 32527755
[TBL] [Abstract][Full Text] [Related]
33. HER2 mutations in Chinese patients with non-small cell lung cancer.
Song Z; Yu X; Shi Z; Zhao J; Zhang Y
Oncotarget; 2016 Nov; 7(47):78152-78158. PubMed ID: 27825109
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer.
Bu S; Wang R; Pan Y; Yu S; Shen X; Li Y; Sun Y; Chen H
Ann Surg Oncol; 2017 Jan; 24(1):291-297. PubMed ID: 27008586
[TBL] [Abstract][Full Text] [Related]
35. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
36. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
37. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
38. Mutation Spectrum of
Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
40. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
